[{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Takeda"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Takeda"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Roche"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Takeda"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Takeda"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Exelixis"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Telaglenastat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous solution","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ NIH","highestDevelopmentStatusID":"8","companyTruncated":"Exelixis \/ NIH"},{"orgOrder":0,"company":"Ipsen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"GSK","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Cabozantinib","moa":"TYK","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0.39000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"Tablet","sponsorNew":"GSK \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Royalty Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"kinase","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Roche"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"Axl tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"PTK","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"AXL kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Merck & Co. Inc","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Merck & Co. Inc"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Exelixis \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Cabozantinib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
